ES2104697T3 - Formulados farmaceuticos. - Google Patents

Formulados farmaceuticos.

Info

Publication number
ES2104697T3
ES2104697T3 ES91907052T ES91907052T ES2104697T3 ES 2104697 T3 ES2104697 T3 ES 2104697T3 ES 91907052 T ES91907052 T ES 91907052T ES 91907052 T ES91907052 T ES 91907052T ES 2104697 T3 ES2104697 T3 ES 2104697T3
Authority
ES
Spain
Prior art keywords
pharmaceutical
formulates
alfaglycerol
formulation
biologically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907052T
Other languages
English (en)
Inventor
Young W Cho
Michael John Flynn
Thomas Smith Shepherd
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Skua Investments Ltd
Original Assignee
Skua Investments Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10673486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2104697(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Skua Investments Ltd filed Critical Skua Investments Ltd
Application granted granted Critical
Publication of ES2104697T3 publication Critical patent/ES2104697T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA FORMULACION FARMACEUTICA QUE COMPRENDE UN MATERIAL BIOLOGICAMENTE ACTIVO TAL COMO INSULINA, ERITROPOIETINA, CALCITONINA Y HORMONA DE CRECIMIENTO, Y, ASOCIADO CON ELLOS, UN FOSFOLIPIDO PARA FORMAR UN MATERIAL QUE SE PRECIPITA EN ALFAGLICEROL PARA LA FORMACION DE LECITINAS QUE SE HAN ENCONTRADO EN LAS CELULAS HEPITELIALES INTESTINALES. LAS PROTEINAS BIOLOGICAMENTE ACTIVAS ADMINISTRADAS ORALMENTE DE ESTA FORMULACION SE ENCUENTRAN BIODISPONIBLES Y SON BIOACTIVAS.
ES91907052T 1990-03-29 1991-04-02 Formulados farmaceuticos. Expired - Lifetime ES2104697T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909007052A GB9007052D0 (en) 1990-03-29 1990-03-29 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ES2104697T3 true ES2104697T3 (es) 1997-10-16

Family

ID=10673486

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907052T Expired - Lifetime ES2104697T3 (es) 1990-03-29 1991-04-02 Formulados farmaceuticos.

Country Status (24)

Country Link
US (1) US5665700A (es)
EP (1) EP0521994B1 (es)
JP (1) JPH05505192A (es)
KR (1) KR100197915B1 (es)
AT (1) ATE154515T1 (es)
AU (1) AU656134B2 (es)
CA (1) CA2079233A1 (es)
CS (1) CS88091A2 (es)
DE (1) DE69126609T2 (es)
DK (1) DK0521994T3 (es)
ES (1) ES2104697T3 (es)
FI (1) FI101043B (es)
GB (1) GB9007052D0 (es)
GR (1) GR3024745T3 (es)
HK (1) HK1004531A1 (es)
HU (2) HUT63341A (es)
IE (1) IE911086A1 (es)
NO (1) NO923768L (es)
NZ (1) NZ237667A (es)
PT (1) PT97199B (es)
RU (1) RU2104715C1 (es)
SG (1) SG54998A1 (es)
WO (1) WO1991014454A1 (es)
ZA (1) ZA912411B (es)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6099856A (en) 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5206219A (en) * 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
US5482706A (en) * 1992-04-17 1996-01-09 Takeda Chemical Industries, Ltd. Transmucosal therapeutic composition
US6916489B2 (en) * 1992-06-15 2005-07-12 Emisphere Technologies, Inc. Active agent transport systems
ES2153385T5 (es) * 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
US5464696A (en) * 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
US20010003001A1 (en) * 1993-04-22 2001-06-07 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6610329B2 (en) 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5744155A (en) * 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
ATE180423T1 (de) * 1993-09-29 1999-06-15 Technobiochip Duenne proteinschichten und zusammensetzungen zu ihrer herstellung
EP0726761B1 (en) * 1993-11-03 2001-01-10 ISOMED, Inc. Microparticular pharmaceutical compositions in micellar form
ES2270426T3 (es) * 1994-03-18 2007-04-01 Supernus Pharmaceuticals, Inc. Sistema de suministros de farmacos emulsionados.
US5851510A (en) * 1994-05-16 1998-12-22 The Board Of Regents Of The University Of Michigan Hepatocyte-selective oil-in-water emulsion
US5858398A (en) * 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
GB9424902D0 (en) * 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5750147A (en) 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
WO1997010197A1 (en) 1995-09-11 1997-03-20 Emisphere Technologies, Inc. METHOD FOR PREPARING φ-AMINOALKANOIC ACID DERIVATIVES FROM CYCLOALKANONES
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
SI9720025A (sl) 1996-03-29 1999-08-31 Emishphere Technologies, Inc. Spojine in sestavki za prenos aktivne snovi
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
CA2258264A1 (en) 1996-06-14 1997-12-18 Emisphere Technologies, Inc. Microencapsulated fragrances and method for preparation
DE19724845A1 (de) * 1996-08-28 1998-03-05 Solvay Pharm Gmbh Verwendung von komplexen Lipiden als stabilisierende Zusätze zu pharmazeutischen Zubereitungen von Verdauungsenzymgemischen
GB9625589D0 (en) 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
US5990166A (en) 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6358504B1 (en) 1997-02-07 2002-03-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5804688A (en) 1997-02-07 1998-09-08 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5830432A (en) * 1997-03-31 1998-11-03 Amur Pharmacuticals, Inc. Phospholipid drug derivatives
US5863944A (en) 1997-04-30 1999-01-26 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5962710A (en) 1997-05-09 1999-10-05 Emisphere Technologies, Inc. Method of preparing salicyloylamino acids
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
US7070799B1 (en) * 1998-02-10 2006-07-04 Generex Pharmaceuticals, Inc. Method for administering insulin to the buccal region
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
SE9801287D0 (sv) * 1998-04-14 1998-04-14 Astra Ab Incorporation of active substances in carrier matrixes
US7498310B1 (en) 1998-08-13 2009-03-03 Beiersdorf Ag Cosmetic or dermatological preparations comprising oligopeptides for lightening the skin of age marks and/or for preventing tanning of the skin, in particular tanning of the skin caused by UV radiation
ES2211151T3 (es) 1998-08-19 2004-07-01 Skyepharma Canada Inc. Dispersiones acuosas inyectables de propofol.
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
GB2344520A (en) * 1998-12-08 2000-06-14 Phares Pharm Res Nv Pharmaceutical carriers comprising lipids and polymers
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6350432B1 (en) 1999-03-19 2002-02-26 Generex Pharmaceuticals Incorporated Pressurized container having an aerosolized pharmaceutical composition
NZ514319A (en) * 1999-03-19 2002-11-26 Generex Pharm Inc Proteinic pharmaceutical agent solubilized in aerosol propellant in a pressurized container
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
EP1175390B1 (en) * 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
PT1181036E (pt) * 1999-04-09 2008-10-03 Ortho Mcneil Pharm Inc Composições farmacêuticas de eritropoietina
DE10038203A1 (de) * 1999-08-06 2001-05-03 Max Delbrueck Centrum Implantierbares Wirkstoffdepot
AU782304B2 (en) * 1999-09-02 2005-07-14 Acologix, Inc. Methods and compositions for reducing serum phosphate levels
US7129274B1 (en) 1999-11-05 2006-10-31 Emisphere Technologies Inc. Phenoxy carboxylic acid compounds and compositions for delivering active agents
US7279597B1 (en) 1999-11-05 2007-10-09 Emisphere Technologies, Inc. Phenyl amine carboxylic acid compounds and compositions for delivering active agents
RU2155602C1 (ru) * 1999-11-30 2000-09-10 Оао "Куантум Сатис" Инсулинсодержащее лекарственное средство для перорального применения и способ его получения
ES2298168T3 (es) * 1999-12-16 2008-05-16 Emisphere Technologies, Inc. Compuestos y composiciones para suministrar agentes activos.
US7785625B2 (en) 2000-01-14 2010-08-31 Lg Life Sciences, Limited Lipophilic-coated microparticle containing a protein drug and formulation comprising same
EP1251867A4 (en) 2000-02-04 2004-12-08 Unigene Lab Inc NASAL CALCITON INFORMATION
US6417237B1 (en) 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US8658202B2 (en) 2001-04-25 2014-02-25 Western University Of Health Sciences Coated drug delivery formulations
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
US6951655B2 (en) 2001-10-11 2005-10-04 Imi Biomed, Inc. Pro-micelle pharmaceutical compositions
KR100441167B1 (ko) * 2001-12-27 2004-07-21 씨제이 주식회사 마이크로에멀젼 예비 농축액 조성물
WO2004032789A2 (en) * 2002-10-09 2004-04-22 The Azza Co., Ltd. Liposomal hgh composition and method for administration thereof
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
US8211448B2 (en) * 2003-07-07 2012-07-03 Nares Ab Microemulsions and its use for preventing airway diseases
JP2005209106A (ja) * 2004-01-26 2005-08-04 Nec Corp 携帯通信端末、受信メール管理方法、プログラムおよび記録媒体
US8236861B2 (en) * 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
CA2560613C (en) 2004-03-22 2015-11-24 Solvay Pharmaceuticals Gmbh Oral pharmaceutical compositions of lipase-containing products, in particular of pancreatin, containing surfactants
KR101243526B1 (ko) * 2004-08-31 2013-03-20 스티펠 리서치 오스트레일리아 피티와이 리미티드 마이크로에멀젼 및 서브마이크론 에멀젼 방법 및 조성물
US8449867B2 (en) 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
EP1652513A1 (en) * 2004-11-02 2006-05-03 Denderah Pharm Sa Reverse micelles based on sterols and acylglycerols and therapeutic uses thereof
GB0428515D0 (en) * 2004-12-30 2005-02-09 Unilever Plc Edible compositions and their preparation
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
EP1933862B1 (en) 2005-09-06 2014-03-26 Oramed Pharmaceuticals Inc. Methods and compositions for oral administration of proteins
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
DE102006056783A1 (de) * 2006-12-01 2008-06-05 Lts Lohmann Therapie-Systeme Ag Zubereitung zur transdermalen Verabreichung von Galanthamin
RU2411039C2 (ru) * 2007-12-26 2011-02-10 Валентина Васильевна Малиновская Иммунокорригирующее средство для лечения заболеваний вирусной этиологии
RU2367472C1 (ru) * 2008-03-17 2009-09-20 Общество С Ограниченной Ответственностью "Технология Лекарств" Парентеральное лекарственное средство и способ его получения
NZ588603A (en) 2008-03-26 2012-03-30 Oramed Ltd Methods and compositions for oral administration of a protein of up to 100000 Daltaons, a first protease inhibitor and a second protease inhibitor wherein said protease inhibitors inhibit trypsin
CN105903005A (zh) 2008-05-05 2016-08-31 奥拉姆德有限公司 用于口服给予艾塞那肽的方法和组合物
WO2010050918A1 (en) * 2008-10-31 2010-05-06 Qinghai Zhang Branched chain detergents for membrane protein structural biology
US20140154377A1 (en) * 2011-04-04 2014-06-05 Dsm Ip Assets B.V. Oil-in-water emulsions comprising a polyunsaturated fatty acid and methods of making the same
US10398762B2 (en) 2012-01-03 2019-09-03 Oramed Ltd. Methods and compositions for treating diabetes
JP6567827B2 (ja) 2012-02-01 2019-08-28 オラムド エルティーディー． プロテアーゼ阻害剤を含有する組成物、該組成物を含む組成物、および、該組成物を製造および使用する方法
CN104902921A (zh) 2013-01-03 2015-09-09 奥拉姆德有限公司 用于治疗nafld、肝性脂肪变性及其后遗症的方法和组合物
EP3820455B1 (en) * 2018-07-10 2024-06-19 Universidade de Santiago de Compostela Nanostructure lipid system

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1180996A (en) * 1967-08-30 1970-02-11 Inst Rech S Chimiques Et Biolo Solubilised Cytochrome C-phospholipid Complexes
US4164573A (en) * 1975-06-13 1979-08-14 Galinsky Alvin M Composition and method for making a suppository for introducing a hypoglycemic agent into a mammal
JPS5517328A (en) * 1978-07-21 1980-02-06 Tanabe Seiyaku Co Ltd Insulin-containing emulsion and its preparation
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
JPS6058915A (ja) * 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
FR2581543B1 (fr) * 1985-05-09 1989-07-07 Tressens Dominique Pharmacotechnie permettant la realisation d'une preparation insulinique active par voie orale
US4849227A (en) * 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
WO1987005505A1 (en) * 1986-03-21 1987-09-24 Eurasiam Laboratories, Inc. Pharmaceutical compositions
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation

Also Published As

Publication number Publication date
NZ237667A (en) 1994-01-26
FI924340L (fi) 1992-09-28
HU211962A9 (en) 1996-01-29
US5665700A (en) 1997-09-09
PT97199B (pt) 1998-07-31
DK0521994T3 (da) 1997-07-07
NO923768D0 (no) 1992-09-28
CS88091A2 (en) 1991-11-12
RU2104715C1 (ru) 1998-02-20
JPH05505192A (ja) 1993-08-05
CA2079233A1 (en) 1991-09-30
NO923768L (no) 1992-09-28
EP0521994B1 (en) 1997-06-18
GB9007052D0 (en) 1990-05-30
HUT63341A (en) 1993-08-30
SG54998A1 (en) 1998-12-21
DE69126609T2 (de) 1998-01-02
GR3024745T3 (en) 1997-12-31
ZA912411B (en) 1992-11-25
FI924340A0 (fi) 1992-09-28
KR100197915B1 (ko) 1999-06-15
PT97199A (pt) 1991-11-29
AU7584291A (en) 1991-10-21
HU9203093D0 (en) 1992-12-28
WO1991014454A1 (en) 1991-10-03
ATE154515T1 (de) 1997-07-15
DE69126609D1 (de) 1997-07-24
FI101043B (fi) 1998-04-15
AU656134B2 (en) 1995-01-27
IE911086A1 (en) 1991-10-09
EP0521994A1 (en) 1993-01-13
HK1004531A1 (en) 1998-11-27

Similar Documents

Publication Publication Date Title
ES2104697T3 (es) Formulados farmaceuticos.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
ES2007607A6 (es) Un procedimiento para la obtencion de un preparado de insulina para la administracion no parenteral.
ES2081384T3 (es) Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.
ES2052829T3 (es) Aminoetiltetralinas substituidas asi como sus analogos heterociclicos.
ES2181723T3 (es) Formulaciones farmaceuticas de factor de crecimiento nervioso.
ES2043897T3 (es) Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
ES2003064A4 (es) Metodos de diagnostico para detectar linfomas en el hombre.
DE3586108D1 (de) Biologisch vertraegliche implantierbare behaelter auf basis von kollagen, die die konservierung und/oder die kultivierung von zellen und/oder die kontrollierte freigabe von aktivsubstanzen ermoeglicht.
ATE196248T1 (de) Vesikel mit gesteuerter wirkstofffreisetzung
DK0859596T3 (da) Vækstfaktorholdige gelformuleringer
MX9201782A (es) Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
ES2183841T3 (es) Formas de dosificacion para administrar un farmasco en una formulacion lquidid.
ES2170259T3 (es) Empleo de lipidos como agentes auxiliares en la obtencion de formas farmaceuticas solidas segun el procedimiento de extrusion en fusion.
FI886019A7 (fi) Laastari vaikuttavien aineiden valvotusti jakamiseksi iholle
NZ320237A (en) Stable pharmaceutical forms of administration containing parathormone
ATE135230T1 (de) Zusammensetzung und behandlung mit biologisch aktiven peptiden und antibiotika
DE59706445D1 (de) Verfahren zur herstellung eines implantates, bestehend aus einem resorbierbaren trägermaterial, eine medizinische wirksubstanz wie ein pharmazeutika, antibiotika, cytostatika oder hormon enthaltend
DE3763851D1 (de) System zur arzneistoffabgabe mit erhoehter bioakzeptanz.
ATE113470T1 (de) Gehirnspezifische zubereitung mit gesteuerter abgabe.
ES2038969T3 (es) Procedimiento para la renaturalizacion de proteinas.
ES2157900T3 (es) Nuevos conjugados de proteinas y policationes.
NO932236L (no) Farmasoeytisk preparat inneholdende probukol med forhoeyet biotilgjengelighet
ES2169089T3 (es) Producto de plantas para controlar las respuestas inmunes en mamiferos y procedimiento para fabricar dicho producto.
ES2118726T3 (es) Factor de crecimiento epidermal como medicamento para la restauracion de neuronas de la substantia nigra en el tratamiento de trastornos neurodegenerativos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 521994

Country of ref document: ES